Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...
Royalty Pharma price target raised to $39 from $38 at BofA
BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...